Inovio Pharmaceuticals, INC Form 4 insider transactions

Director Wendy L. Yarno of Inovio Pharmaceuticals, Inc. was granted stock options and restricted stock units on May 20, 2026, as part of the company's non-employee director compensation policy.

Jay Shepard, a Director at Inovio Pharmaceuticals, Inc., acquired 41,800 stock options and 34,200 restricted stock units.

Director Ann Miller of Inovio Pharmaceuticals, Inc. (INO) acquired stock options and restricted stock units under the company's incentive plan.

David B. Weiner, a Director at Inovio Pharmaceuticals, Inc., acquired 41,800 stock options and 34,200 restricted stock units.

Inovio Pharmaceuticals director Lota S. Zoth was granted stock options and restricted stock units under the company's incentive plan.

Director Simon X. Benito of Inovio Pharmaceuticals, Inc. acquired 41,800 stock options and 34,200 restricted stock units.

Michael John Sumner, Chief Medical Officer of Inovio Pharmaceuticals, Inc., reported significant stock transactions including the acquisition of restricted stock units and stock options.

Inovio Pharmaceuticals CFO Peter Kies acquired shares through restricted stock units and stock options, with details on vesting schedules and tax withholding.

Jacqueline Elizabeth Shea, CEO of Inovio Pharmaceuticals, reports significant equity transactions including vesting of restricted stock units and stock option grants.

Jacqueline Elizabeth Shea, CEO and Director of Inovio Pharmaceuticals, reported a transaction involving the sale of 7,717 shares of common stock.

Inovio Pharmaceuticals CFO Peter Kies reported transactions involving restricted stock units and common stock, including tax withholdings.

Laurent Humeau, Chief Scientific Officer at Inovio Pharmaceuticals, reported the vesting of restricted stock units and the subsequent withholding of shares for tax obligations.

Michael John Sumner, Chief Medical Officer of Inovio Pharmaceuticals, reported transactions involving restricted stock units, including vesting and tax withholding.

INOVIO Pharmaceuticals' Chief Medical Officer, Michael John Sumner, reported changes in beneficial ownership following the vesting of restricted stock units.

INOVIO's Chief Scientific Officer, Laurent Humeau, received 26,840 stock options and 21,560 restricted stock units as part of compensation.

INOVIO Pharmaceuticals CEO Jacqueline Shea was granted 97,240 stock options and 78,760 restricted stock units.

INOVIO Pharmaceuticals' Chief Medical Officer, Michael John Sumner, was granted 36,832 stock options and 29,608 restricted stock units effective March 4, 2026.

INOVIO Pharmaceuticals' CFO, Peter Kies, was granted 31,240 stock options and 25,520 restricted stock units on March 4, 2026, as part of his compensation.

INOVIO Pharmaceuticals' Chief Scientific Officer, Laurent Humeau, reported the vesting of restricted stock units and subsequent share withholdings for tax obligations.

INOVIO Pharmaceuticals CFO Peter Kies reported the vesting of restricted stock units and subsequent share disposals for tax obligations on February 26, 2026.

INOVIO Pharmaceuticals CEO Jacqueline Elizabeth Shea reported the vesting of restricted stock units and subsequent share withholding for tax obligations on February 26, 2026.

INOVIO Pharmaceuticals' Chief Medical Officer, Michael John Sumner, reported the vesting of restricted stock units and subsequent tax-related share withholding.

INOVIO Pharmaceuticals Director David B. Weiner acquired 972 shares of common stock through the vesting of restricted stock units.

Inovio Pharmaceuticals' Chief Medical Officer, Michael John Sumner, has filed a Form 4 disclosing the upcoming vesting of 2,916 restricted stock units on June 30, 2025, completing the vesting schedule for a prior grant.

Inovio Pharmaceuticals' CEO, Jacqueline Shea, reports the acquisition of restricted stock units and stock options, signaling potential future ownership in the company.

Laurent Humeau, Chief Scientific Officer of Inovio Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Director Lota S. Zoth reports the vesting and disposal of restricted stock units resulting in the acquisition and disposal of common stock.

Director Ann Calby Miller reports the vesting and disposal of restricted stock units resulting in a change in beneficial ownership of Inovio Pharmaceuticals stock.

Director Jay Shepard reports the vesting and disposal of restricted stock units into common stock on May 21, 2025.

Director Simon X. Benito reports a transaction involving Inovio Pharmaceuticals common stock and restricted stock units.